Naomi Bertine Klarenbeek

Naomi Bertine Klarenbeek

Auto-generated profile, based on publicly available information

Naomi Bertine Klarenbeek

Centre for Human Drug Research, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2012 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LDL. Dirven
L. Dirven
NKN. B. Klarenbeek
N. B. Klarenbeek
MBMaries van den Broek
Maries van den Broek
JGJ. H. L. M. van Groenendael
J. H. L. M. van Groenendael
PSP. B. J. de Sonnaville
P. B. J. de Sonnaville
CAC. F. Allaart
C. F. Allaart

9 October 2024 in Experimental Dermatology
Verified
Journal Article
Open access
JRJannik Rousel
Jannik Rousel
CMCatherine Mergen
Catherine Mergen
MBMenthe E. Bergmans
Menthe E. Bergmans
NKNaomi B. Klarenbeek
Naomi B. Klarenbeek
TKTessa Niemeyer‐Van der Kolk
Tessa Niemeyer‐Van der Kolk
RRRobert Rissmann
Robert Rissmann
Psoriasis is an inflammatory skin disease associated with an impaired skin barrier. The skin barrier function is dependent on the extracellular lipid matrix which surrounds the corneocytes in the stratum corneum. Ceramides comprise essential components of this matrix. Alterations in the stratum corneum ceramide profile have been directly linked to barrier dysfunction and might be an underlying factor of the barrier impairment in psoriasis. In this study, we investigated the ceramide profile and barrier function in psoriasis. Lesional and non‐lesional skin of 26 patients and 10 healthy controls were analysed using in‐depth ceramide lipidomics by liquid chromatography‐mass spectrometry. Barrier function was assessed by measuring transepidermal water loss. Lesional skin showed a significant decrease in the abundance of total ceramides with significant alterations in the ceramide subclass composition compared to control and non‐lesional skin. Additionally, the percentage of monounsaturated ceramides was significantly increased, and the average ceramide chain length significantly decreased in lesional skin. Altogether, this resulted in a markedly different profile compared to controls for lesional skin, but not for non‐lesional skin. Importantly, the reduced barrier function in lesional psoriasis correlated to alterations in the ceramide profile, highlighting their interdependence. By assessing the parameters 2 weeks apart, we are able to highlight the reproducibility of these findings, which further affirms this connection. To conclude, we show that changes in the ceramide profile and barrier impairment are observed in, and limited to, lesional psoriatic skin. Their direct correlation provides a further mechanistic basis for the concomitantly observed impairment of barrier dysfunction.

1 June 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
RKR Koevoets
R Koevoets
LDL Dirven
L Dirven
NKN B Klarenbeek
N B Klarenbeek
MKM V van Krugten
M V van Krugten
HRH K Ronday
H K Ronday
CAC F Allaart
C F Allaart
Objective To evaluate the contribution of joint space narrowing (JSN) and erosions in general and in four different joint groups in relation to physical disability in rheumatoid arthritis (RA). Methods 5-year follow-up data from the Behandel Strategieën (BeSt) trial were used, where 508 patients with recent onset RA were treated aiming at a disease activity score ≤2.4. Joint damage was assessed annually and scored according to the Sharp-van der Heijde method. Physical disability was measured 3-monthly with the Health Assessment Questionnaire (HAQ). Generalised Estimating Equations analyses were performed to assess the relationship between the HAQ and JSN scores and erosions scores, separately and in joint groups. Results Overall, damage scores were low, and neither total JSN nor erosions showed a significant effect on HAQ (β=0.001 95% CI −0.003 to 0.004 and β=0.002 95% CI −0.001 to 0.006, respectively). Of the total damage scores per joint group, damage in the wrist shows a trend for association with physical disability displaying the largest effect size (β=0.005 95% CI 0.000 to 0.011). Also in the analysis with erosions per joint group, the wrist was most strongly related with physical functioning (β=0.016 95% CI 0.003 to 0.029); in the analysis with JSN per joint group no joint group was significantly related to the HAQ. Analysis of all erosion and narrowing scores per joint group in one model reveals only erosions in the wrist to be independently associated with impaired physical functioning (β=0.017 95% CI 0.003 to 0.030). Conclusions Joint damage in the wrist, erosions more than JSN, is associated with impaired physical functioning even in patients with early RA with limited overall damage after 5 years tightly controlled treatment.

1 January 2011 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
EKE van der Kooi
E van der Kooi
NKN B Klarenbeek
N B Klarenbeek
MGM Güler-Yüksel
M Güler-Yüksel
PKP J S M Kerstens
P J S M Kerstens
PLP A H M van der Lubbe
P A H M van der Lubbe
CAC F Allaart
C F Allaart
Objective To assess the relationship between a decrease in disease activity score (DAS) and functional ability during 5 years of DAS-steered treatment in recent-onset rheumatoid arthritis (RA) patients, taking into account absolute DAS levels and follow-up duration. Methods Data from the BeSt study were used, in which treatment was aimed at achieving DAS ≤2.4. The longitudinal relationship between 3-monthly measured DAS and health assessment questionnaire (HAQ) score was assessed using linear mixed modelling during 5 years of treatment, with DAS and HAQ 3 months earlier, change in DAS in last 3 months (delta DAS), time (log-transformed) and their interactions as determinants. Results Predictors for HAQ were: previous DAS, delta DAS, ln time, the interaction previous DAS×delta DAS, and previous HAQ. The interaction ln time×delta DAS was non-significant, indicating that the association between delta DAS and HAQ was independent of follow-up duration. A decrease from a higher DAS was associated with a smaller HAQ decrease than for a similar decrease from a lower DAS, indicating a non-linear relationship between DAS and HAQ. Conclusion At any time during 5 years of follow-up, a decrease in DAS was associated with a better functional ability. The magnitude of HAQ improvement depends on the DAS decrease and on the absolute DAS level.

25 July 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
MRMarella C. E. van Ruissen
Marella C. E. van Ruissen
SKSebastiaan J. W. van Kraaij
Sebastiaan J. W. van Kraaij
JWJana Wolfova
Jana Wolfova
FHFranziska E. Herrmann
Franziska E. Herrmann
YBYanick Botilde
Yanick Botilde
NKNaomi B. Klarenbeek
Naomi B. Klarenbeek
BI 1839100 is a selective antagonist of transient receptor potential ankyrin 1 (TRPA1). Topically applied TRPA1‐agonistic allyl isothiocyanate (AITC), inducing non‐invasively measurable increased dermal blood flow (DBF), is known as a skin challenge model to assess TRPA1‐target engagement and pharmacodynamic (PD) activity of TRPA1 inhibitors. This study aims to support the pharmacological rationale of BI 1839100 based on preclinical evidence and to test its safety, pharmacokinetic (PK) profile, and PD effects using an AITC skin challenge in a phase I first‐in‐human clinical study. In vitro and in vivo experiments were conducted in human TRPA1‐overexpressing human embryonal kidney (HEK)293 cells and mice, respectively. Exposure to BI 1839100 and AITC demonstrated a BI 1839100 exposure‐related reduction of AITC‐induced Ca2+ increase in HEK293 cells and skin edema in mice. Healthy male participants, aged 18–45 years, were randomized within 10 cohorts in the single‐ascending dose part (n = 80) and two cohorts in the PD part (n = 32). All received single doses of BI 1839100/placebo followed by safety and PK measurements. In the PD part, participants underwent an AITC skin challenge twice; at baseline and at time to peak drug concentration after BI 1839100/placebo administration. No significant imbalance in occurrence of adverse events was detected between single doses of BI 1839100 up to 300 mg and placebo, and PK profiles were dose‐proportional in the 40–300 mg range. BI 1839100 demonstrated a dose‐dependent inhibitory effect on DBF after the AITC skin challenge, indicating TRPA1‐targeted pharmacological activity and potentiating BI 1839100 for further clinical development for a broad range of TRPA1 antagonistic applications.

15 November 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
MRMarella Cornelia Elizabeth van Ruissen
Marella Cornelia Elizabeth van Ruissen
MDMenno van Diemen
Menno van Diemen
LBLiza Botros
Liza Botros
ITIngrid Tomljanovic
Ingrid Tomljanovic
HAHind Achbo
Hind Achbo
MMMatthijs Moerland
Matthijs Moerland
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials. This single‐center experimental study evaluated the intradermal lipopolysaccharide (id LPS) challenge model as a tool to induce and characterize vascular leakage in healthy participants. Eight participants (male:female = 4:4) received id LPS in the volar forearms, followed by serial pharmacodynamic assessments, including imaging and suction blister induction up to 9 hours after injection. Id LPS administration resulted in significant increases in skin perfusion ( P < 0.0001), erythema ( P = 0.0013), and skin volume ( P = 0.0008), indicating initial stages of inflammation and fluid extravasation. Blister fluid analysis revealed elevated extravascular concentrations of albumin ( P = 0.0011), total protein ( P < 0.0001), and neutrophils ( P = 0.0342), supporting the presence of vascular leakage. Moreover, the expression of endothelial activation markers VCAM‐1 ( P = 0.0015), ICAM‐1 ( P = 0.0004), ITGB1 ( P = 0.01), and E‐selectin ( P = 0.0218) increased significantly. Disruption of endothelial cell–cell integrity was supported by increased expression of VE‐cadherin ( P = 0.0002) in blister fluid. These findings support the applicability of the id LPS model for the induction of vascular leakage in humans. This model holds potential as a translational tool for evaluating the pharmacodynamic responses of vascular leakage‐targeting drugs in early clinical development.